FDA approves cabozantinib for differentiated thyroid cancer

FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news